According to the report, the global osteoporosis drugs market was valued at US$ 11.5 Bn in 2018 and is anticipated to contract at a CAGR of 0.3% from 2019 to 2027
- According to Transparency Market Research’s latest report on the global osteoporosis drugs market for the historical period 2017–2018 and forecast period 2019–2027, rising prevalence of osteoporosis, growing aging population which is more prone to osteoporosis, and introduction of new therapies are projected to drive the global Osteoporosis Drugs market during the forecast period
- According to the report, the global osteoporosis drugs market was valued at US$ 11.5 Bn in 2018 and is anticipated to contract at a CAGR of 0.3% from 2019 to 2027
Read Report Overview - https://www.transparencymarketresearch.com/osteoporosis-drug-market.html
High Incidence and prevalence of osteoporosis coupled with growth in geriatric population: Key Driver
- Rising prevalence of osteoporosis is considered an important driver of the market, as more patients would increase demand for the drugs. Moreover, due to absence of any substantial substitute, such as surgery, demand for osteoporosis drugs is increasing constantly.
- For instance, according to International Osteoporosis Foundation, Osteoporosis causes more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds and also it is estimated to affect 200 million women globally.
- Furthermore, rising geriatric population is considered an important factor for growth of the market in coming years. Individuals above 50 years of age are at the greatest risk of developing osteoporosis and related fractures due to hormonal changes.
- The number of people aged 65 years and above is projected to increase from 524 million in 2010 to approximately 1.5 billion in 2050. This high proportion of geriatric population is more prone to osteoporosis.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=133
Patent expiry of blockbuster drugs and dynamic changes in pricing due to generics restrain market growth
- Patent expiry and loss of exclusivity are considered major restraints of the osteoporosis drugs market. As the generic equivalents of branded drugs are manufactured and marketed at 1/10th of the price of the original branded drug, loss of patent exclusivity of a branded drug results in drastic revenue reduction amounting to almost 35% - 40% in the first year.
- This low cost of generics results in higher consumption, although, generic drugs are not able to achieve or exceed the overall sales of the branded formulation.
Request for Analysis of COVID-19 Impact on Osteoporosis Drugs Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=133
Global Osteoporosis Drugs Market: North America Dominated the global market
- On the basis of region, the osteoporosis drugs market is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
- North America region dominated the global market owing to the presence of large number of osteoporosis patients, world-class medical infrastructure, rising awareness about the disease and its treatment and proper utilization of technologically sound devices for diagnosis purpose.
- However, Asia-Pacific region is considered as the most promising market during the forecast period from 2014 to 2020. The growth is mainly attributed to factors such as steadily increasing incidence rate of osteoporosis, increasing medical expenditure, increased healthcare awareness towards diagnosis and treatment of osteoporosis and dietary habits and lack of nutritious foods.
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=133
Global Osteoporosis Drugs Market: Competitive Landscape
- This report profiles major players in the global osteoporosis drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
- The global osteoporosis drugs market is highly fragmented, with the presence of a number of international as well as regional players
Pre Book Osteoporosis Drugs Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=133<ype=S
Global Osteoporosis Drugs Market: Key Developments
Key players in the global osteoporosis drugs market are engaged in regulatory approvals, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global osteoporosis drugs market. A few expansion strategies adopted by players operating in the global Osteoporosis Drugs market are:
- On April 09, 2019, Amgen Inc. has got U.S. FDA approval for its drug EVENITY (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture.
- On August 05, 2019, Radius Health, Inc., Initiated the Phase 3 wearABLe Study of Abaloparatide-Patch in Postmenopausal Osteoporosis Patients at High Risk for Fracture.
The report on the global Osteoporosis Drugs market discussed individual strategies, followed by company profiles of manufacturers of Osteoporosis Drugs. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global Osteoporosis Drugs market.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453